Eli Lilly and Nvidia announced a strategic partnership to build what they describe as the most powerful supercomputer owned by a pharmaceutical company, aimed at training larger AI models for drug discovery and molecular design. Lilly said the infrastructure will accelerate in-house AI capabilities across chemistry, biology and clinical modeling, adding GPU-accelerated libraries and frameworks for omics and model training. Nvidia framed the deal as national-scale industrial collaboration to keep U.S. leadership in biomedical AI. The effort signals large-cap pharma doubling down on proprietary compute to compress discovery timelines and scale generative biology efforts.